Conjugated Estrogens and Bazedoxifene (Duavee)
Questions a plan sponsor actually asks.
What is Conjugated Estrogens and Bazedoxifene used for?
Conjugated Estrogens and Bazedoxifene is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Conjugated Estrogens and Bazedoxifene?
No. Conjugated Estrogens and Bazedoxifene is brand-only with no generic equivalents currently in market.
How much does my plan pay for Conjugated Estrogens and Bazedoxifene?
Across 329 Part D plans, Conjugated Estrogens and Bazedoxifene averages $6.48/unit (NADAC). Lowest available: $6.48/unit. Highest in distribution: $6.48/unit.
Is Conjugated Estrogens and Bazedoxifene on the FDA shortage list?
No. Conjugated Estrogens and Bazedoxifene is not currently on the FDA Drug Shortage Database.
3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.